Friday, February 09, 2007

We'll Miss You Molly



Yes, I'm late to the game here. I just wanted to publicly pay my respects to Molly Ivins, the great (and unforunately, recently deceased) American political writer and rabblerouser.

The above drawing is from Idrewthis.org, which has quite the interesting collection of political cartoons. Don't bother going to his site if you are a big Bush/Cheney fan -- his site will only make you mad.

Zyprexa, NAMI, and Operation Restore Confidence

Furious Seasons is starting to write on the Zyprexa documents posted on his site. He details that Lilly planned to give a huge grant to NAMI to "help educate physicians and patients on the inherent risks of diabetes -- regardless of the antipsychotic" -- in other words, to help deflect the attention being given to Zyprexa. This seems a strange positon for a patient advocacy group such as NAMI to find itself in.

There is more posted on the site about the relationships between NAMI and Lilly. The memo also noted that Michael Fumento was taking a positive position about Zyprexa in his writings. What is unknown is whether Fumento received any Lilly funding.

Lilly's attempt to combat Zyprexa's crumbling reputation was apparently called "Operation Restore Confidence." Is your confidence restored?

Read the whole piece at Furious Seasons and be on the lookout for more.

The BEST Way to Grade Papers

This is G-R-E-A-T. I have found my grading soulmate. Please see the following link to see it. Hilarious. Brilliant. Now I know how I'll grade the next batch of papers.

Seroquel for Everything Update: GAD

I have mentioned earlier that Seroquel is being studied as a treatment for virtually every psychiatric disorder under the sun. You can now access a very brief outline of the latest Seroquel study for generalized anxiety disorder here.
The official title: An International, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (Seroquel SR™ ) in the Treatment of Generalized Anxiety Disorder (SILVER)
Virtually all big drug trials now have cute acronyms. Seroquel has used BOLDER before (here and here) and now it's SILVER. If only the academic researchers associated with these studies put as much thought and time into their work on the data analysis and writeup of these studies as the marketing teams did in coming up with the acronyms.

And how, exactly, did SILVER come from the above title? Seems like a stretch...

But wait, there's more.

Here's another study. In this one, Seroquel will be compared with placebo in the treatment of GAD in elderly folks. And still another study, this one apparently comparing Seroquel to placebo in the treatment of GAD, again. How about another one -- this one comparing Seroquel to Lexapro for GAD.

And another one -- this one apparently will put folks on Seroquel for a while, then follow those who show improvement. Some who improve will get switched to a placebo while some stay on Seroquel. If people switched to placebo show more anxiety, then AstraZeneca and its allied academics will say that Seroquel is a good long-term treatment. Of course, maybe it's just that Seroquel has withdrawal symptoms, and that is what caused the anxiety. Yes, this is all hypothetical, but it is the card that has been played time and time again for other psychiatric disorders.

Havidol For All



That's right folks. A brilliant spoof (or is it real?) for the new wonder drug Havidol is available here. Pretty good stuff. It is the only known treatment for Dysphoric Social Attention Consumption Deficit Anxiety Disorder (DSACDAD) and it is clinically proven.

Hat Tip: Mind Hacks, Furious Seasons, PharmaGossip.

Puff Pieces and Ghostwriting

The journal European Neuropsychopharmacology ran a supplement issue in Sepotember 2006 titled:

September 2006, Pages S149-S155
From the Clinic to the Community: Treating the Whole Schizophrenic Patient and Innovation in Psychiatric Therapy: The Promise of the New Antipsychotics

What is a supplement issue? It is a journal issue paid for by drug companies (GlaxoSmithKline, in the case of this particular supplement) which control the content contained in this issue. Isn't that just an advertisement, you ask? I'm not sure what else you could call it, but the words independent and scholarly certainly do not apply.

Siegfried Kasper has an advertisement, er, article in which he says (with my emphasis): "The use of atypical agents to address the full range of psychotic symptoms with minimal adverse effects should ensure improved functionality and an improved patient quality of life in patients with schizophrenia: both can be regarded as positive reinforcers for long-term compliance."

Who is Siegfried Kasper? Let's find out. David Healy was given a ghostwritten article a few years ago to which he was expected to attach his name. However, he made several changes to the paper. In fact, it was altered to the extent that it no longer served its originally intended purpose as an advertisement for milnacipran. So, the paper that was originally ghostwritten and sent to Healy was forwarded to an Austrian psychiatrist. The psychiatrist was Siegfried Kasper and he attached his name to the paper, making not a single change. In other words, someone wrote an article intended to serve as an advertisement for milnacipran, and Kasper affixed his name to it as if it were his own work. In fact, to quote from the Guardian...

… the original, ghostwritten article which contained what they described as "the main commercially important points" was to be there too. "Siegfried Kasper has kindly agreed to author this one," they said. The name of Professor Kasper of the University of Vienna, editor of the journal, duly appeared on the unaltered, published article, complete with the original references to Dr Healy's work. Professor Kasper told the Guardian that he was happy with the content of the article.

According to one source, Kasper has “authored over 800 research reports and reviews.” One is left to wonder how many of those were actually written by him versus written by ghostwriters and rubber stamped under his name.

When academics are willing to sell their names and reputations, how can the university system function as an independent check on the claims made by drug manufacturers?

Zyprexa Editorial

No, not my editorial. I think my views on this have already been made clear. Courtesy of Health Care Renewal, an excellent editorial from Richard Zitrin is reproduced and Roy Poses' excellent commentary follows, which includes the following:
So let's see, continuing news stories and commentaries suggest Eli Lilly has been trying to hide unfavorable information about its blockbuster drug Zyprexa, the company's share price is falling, and yet its top executives are getting large increases in their already lavish compensation.
Good point (as usual), Roy. Read the whole piece. It's got secrecy, executive compensation, lawyers, Lilly, and Zyprexa all in the same post. You can't top that.

Nicorette or Cold Turkey?

BrandweekNRX has a very interesting story about the government attempting to push GlaxoSmithKline's Nicorette rather than going "cold turkey" to stop smoking. According to some evidence, it appears that there is actually little data to support such an idea -- meaning that cold turkey is no less effective than Nicorette. I am not directly familiar with the evidence on this point, but if true, that's sure interesting.

But there's another layer to the story. The folks writing the government guidelines for how to best quit smoking -- well, some of them are on GSK's payroll. How convenient...

Tor and Big Brother

The Chronicle of Higher Education has an interesting story from a professor who was asked to stop using Tor because it "violates university policy."

For those who don't know, Tor is an application that allows users to browse the internet anonymously. For people in countries with restrictive governments, Tor is one way to get around "blocked sites." For people working in the drug industry, Tor is a great way to browse sites like PharmaGossip without a trip to the guillotine courtesy of one's employer. Any site to which you travel can track the IP address of your computer as can the network which you are using, so I am a huge fan of Tor, as it is one of the few ways to get around people who want to become acquainted with your browsing habits.

To quote Dr. Cesarini (the "accused" professor):
When I cover online censorship in countries with no free press, I focus on how those countries rely on hardware, software, and phalanxes of people to make sure citizens can reach only government-approved media. Crackdowns on independent journalists, bloggers, and related dissidents all too often result in their being beaten, incarcerated, or worse. Technologies like Tor represent a beacon of freedom to people in those countries, and I would be doing my students a disservice if I didn't mention it.
Here is part of Cesarini's account regarding his interaction with the investigators:
They then gave me a copy of the university's responsible-use policy, which employees must agree to abide by when we first sign up for our e-mail accounts. They pointed out that my actions violated at least three provisions of that policy.

I wasn't particularly impressed. I had helped edit and revise that policy when I worked for the information-technology office before I earned my Ph.D., and I knew that neither Tor nor any similar program had existed when the policy was first written. I also knew that the provisions in question were vague.

Read the whole article. I can see why universities would hate people using Tor (it is discussed in the article) but it really does seem an infringement of freedom to tell people that they cannot browse anonymously.

Thursday, February 08, 2007

PharmaGiles Does it Again

In yet another hilarious mockumentary post, PharmaGiles goes nuts. Here's a snippet:
Our first problem was finding a large population of sexually dysfunctional women who would be prepared to volunteer for such a study. Fortunately, we realised that our entire HR division was staffed exclusively with such women, and so we were able to get the trial up and running fairly quickly. After a year, however, we were forced to conclude that the trial results did not demonstrate any advantage over existing treatments for low female sexual response, such as Fyngeryn™® and Mufdyvin®™.
Read the whole thing over at the PharmaGiles site. If you don't read it, you'll miss out on such beauties as Wang Chung Pharmaceuticals, the words of Orville Huckster, allegedly fake examples of data manipulation, and much more.

A Must Take Survey

Over at the Pharma Blogosphere site, you can take a survey about blogs related to the wonderful and sometimes wild world of pharmaceuticals. Rate your favorite and least favorite blogs and make suggestions. You'll get a cool bit of info (actually a document with several cool bits of info) for completing the survey.

Take the survey here.

Interview with the Gooz

Over at eDrugSearch is a brief and excellent interview with Merrill Goozner, journalist and author of the great book, the $800 Million Pill. There are so many quotable quotes in the interview that I'm tempted to steal them all. Instead, I'll leave you with just one teaser:
Goozner: If half of industry R&D is spent on developing drugs that add little or nothing to physicians’ ability to fight disease, and a substantial portion of industry marketing costs go to promote these drugs, or to whatever extent this is true, then the cost of drugs could be reduced by that amount without any harm to public health. Indeed, I would argue that eliminating these wasteful expenditures would free up industry resources to pour into more speculative (difficult) R&D projects...
There's much more and I encourage everyone to check it out.

Evidence Biased Medicine (To the Core)

The Last Psychiatrist wrote an excellent comment regarding a post describing how "scientific" data and/or its analysis and interpretation are often cooked by ghostwriters and/or friendly academics. He discussed how the whole process of publishing research is biased, a point that will be discussed in depth throughout this lengthy post. The Last Psychiatrist said:
Sure Pharma puts pressure on doctors, and forces through studies that are helpful to them (and suppresses those that hurt them).

But the real problem in medicine is the academic centers. Their bias is dangerous because it's so subtle and pervasive.

If Astra Zeneca does a Seroquel study, I think we can guess the bias. But when Assistant Professor Jones does a Seroquel study-- funded by the NIH-- is that study magically free of bias? What about Jones's beliefs on medications (he thinks pharmacotherapy is a gold mine, or is he anti-drugs and pro therapy?; maybe he's pro-seizure drugs (Depakote, Lamictal) and anti-antipsychotics (or the other way around?) Maybe his mentor gets AZ money (which is used to pay his salary through the university?) Maybe NIH has a stake in getting expensive drugs like Seroquel to look bad (e.g. CATIE?)

And journals are worse: think that the editors of a journal don't have biases-- even direct pharma ones?

And the three peer reviewers?

Ever wondered what articles don't get accepted for publication, and why (and I say this as someone who has a pretty high rate of publication success).

And why do those journals-- which publish public data-- cost $1000/yr and can't be accessed by the public?

The first and most important step to fixing medicine is abandoning the journal system. All articles, including the raw data that generated them, photos, scientific notebooks, etc, should go online. Let the world vet the data.
I agree with the great majority of what he said. I find it hard to believe that NIH is against expensive medications, since many of the NIH folks have ties with drug companies which are, of course, pushing newer and more expensive meds.

We have to keep in mind that the whole "scientific" peer-review process includes a lot of bias.

Let's review how studies go from a set of numbers into a published manuscript. It may sound like a dull process, but this is the foundation of our so-called evidence base in medicine, so it is actually very important to understand.

How is it biased? Let me count the ways...

Step 1. Analyzing data and writing the paper. Researchers transform a bunch of numbers into a paper.

1) It's anyone's guess as to whether the researchers have
actually seen the data upon which they are to base their writings. In some cases, it is unlikely that they have. So the company could have already made some alterations to the data -- it's unclear how often this happens, but it is certainly a possibility in some (hopefully rare?) instances.

2) The company can analyze the data in any way it sees fit.
Go to Aubrey Blumsohn's site for an excellent example of why this can be problematic. Company statisticians can cook the books either overtly or in a more subtle manner (like they did with the Seroquel data -- here and here).

3) The company can interpret the numbers in any way it wants.
For example, if someone committed suicide while taking a drug, the drug couldn't have caused it, but if the patient committed suicide on a placebo, then the placebo caused it. Even when the data are not favorable, positive conclusions are reached in most instances (here, for example).

4) The company can bury any unfavorable data.
Suppose that depression was measured in five different ways. If a couple of those measures yielded unfavorable results, toss them aside and act as if they never existed. Don't even mention that they existed in the article.

5) When all else fails, deep-six the study.
If the data still fail to prove favorable, just bury the entire thing -- don't publish it. When lawyers and/or researchers get their hands on unpublished data, it quite often shows unfavorable results which the sponsoring company thought best to bury.

Step 2. Peer Review. The paper is then sent off to "experts" for peer review. As the LP said earlier, these folks (including me) have their biases. Indeed, one of my peers has called the peer review process "a Rorscach test of the reviewers," meaning that you can easily see their biases through the reviews. Most reviewers of psychiatry journals have ties to industry which have likely shaped their beliefs to roughly the following: "Drugs are safe and effective," though biases will vary.

The comments of these expert reviewers are quite important in determining whether the study will get published.

Here's what one former journal editor, Richard Smith (British Medical Journal) had to say about peer review (with my emphasis):
The problem with peer review is that we have good evidence on its deficiencies and poor evidence on its benefits. We know that it is expensive, slow, prone to bias, open to abuse, possibly anti-innovatory, and unable to detect fraud. We also know that the published papers that emerge from the process are often grossly deficient.
Hmmm. No, this is not sour grapes on my part -- I've little to complain about in terms of being published. But myself and many other researchers are often befuddled by the whole process -- it often seems that reviewers are unhelpful.

Does peer review help, at least a little bit? I think so. Does it solve the problem of low-quality papers hitting journals, which are then turned into marketing copy by the drug and device industry? Obviously not.

Step 3. Editoral Decision. The editor chooses whether to accept the paper (usually after some revisions are made).

Journal editors frequently have huge ties to industry. Just google the names of many editors and you'll find that they have received funding from a lot of different sources. We also know that sometimes peer reviewers make good comments, yet the editor chooses to ignore them.

Note that nearly all journals are a for-profit entity. How can they make money? Advertising, subscriptions, and reprints. If a journal runs an article favorable to industry (saying that vagus nerve stimulation is great for depression, for example), then it is likely that the company will buy thousands of reprints for dissemination to physicians. The journal is making good money from each reprint and can make tens of thousands or even up to a million dollars from reprints of a study. A study that is unfavorable or irrelevant to industry is not going to generate revenue for the journal. So from a business standpoint, it makes more sense to print studies (like this or this) that are written from a slant of favoring a product than to run something less industry-friendly.

What to do?

Start by making all trial information publicly available.
The Last Psychiatrist said it. Richard Smith said it, and I agree with it. I don't think we should abolish journals altogether -- seems extreme, but making data publicly available -- that's an excellent idea.

Penalize those who engage in misconduct
As Fiona Godlee (editor of the British Medical Journal) stated recently:

So what can we do to change the blind-eye culture of medicine? In the interests of patients and professional integrity I suggest intolerance and exposure.

--SNIP--

And if journals discover authors who are guests on their own papers, they should report them to their institution, admonish them in the journal and probably retract the paper.

Reputations for sale are reputations at risk. We need to make that risk so high it's not worth taking.

Other thoughts?

Update (2-9-07): Quite a few people have been reading this via reddit. To see comments regarding this post at reddit, click the following link.

Too Kind

I’d like to thank PsychSplash for the friendly review of my site. At one point, he wrote:

CL Psych writes with raw yet controlled frustration, that borders nicely on sheer disbelief and intellectual curiousity. Do not get me wrong, “Clinical Psychology and Psychiatry: A closer look” is not an open diatribe on drug companies or psychological treatments, rather it is a realistic appraisal of the claims made by companies with vested interests in good results.

Thanks mate! PsychSplash is a site that, among other things, reviews psychology-related sites. For my psychology-oriented readers, it’s a nice gateway to a variety of interesting sites and blogs.

An SSRI Was All That Was Missing...

…from this patient’s interesting drug cocktail, reported in the Journal of the Association of Physicians in India. The patient was diagnosed with paranoid schizophrenia and she overdosed, downing 22 days worth of medication simultaneously. On a daily basis, she was prescribed: 4mg risperidone (Risperdal), 40mg ziprasidone (Geodon), 1g divalproex (Depakote), 2 mg of trihexyphenidyl (Artane; likely to control side movement disorder side effects from her antipsychotics), and 3mg of clonazepam (Klonpin).

If you’re keeping score at home, that’s:
*2 antipsychotics
*1 medication to control side effects of antipsychotics
*1 “mood stabilizer”
*1 antianxiety medication

The news flash is not that she overdosed; it’s that such combinations are prescribed with some frequency. This report just drives home the point what many of us already know – psychiatric polypharmacy (the prescription of multiple psych meds at once) has gone wild, and apparently this is not limited to Europe and the USA.

The good news is that the patient survived her overdose. The bad news is that we have no idea of how prescribing so many meds may impact the functioning of people.

However, not all cases of psychiatric polypharmacy have such benign endings. Especially when the cases involve young children diagnosed with (what else) bipolar disorder. Read more about a very sad case over at Furious Seasons.

Wednesday, February 07, 2007

Suicide? Not a Problem

A study in International Clinical Psychopharmacology compared three doses of agomelatine to paroxetine (Paxil or Seroxat) and placebo in the treatment of depression. I will write about the efficacy of agomelatine soon, but this post focuses on the alleged safety of the medications.

In the abstract, the authors wrote, “Agomelatine, whatever the dose, showed good acceptability with a side-effect profile close to that of placebo.” In the discussion, they state “Agomelatine is very well tolerated with an adverse event profile close to placebo.”

Now we are going to compare the rate of suicide and suicide attempts on medication to the rate of suicides and suicide attempts on placebo. Here is the data from the study, which is quoted directly (with added emphases):

During the study, two participants committed suicide, one [of 147 patients] on paroxetine after 11 days of treatment, one [of 137 patients] on agomelatine 25 mg of treatment after 10 days of treatment (both deaths being unrelated to treatment according to the investigator's opinion)... There were seven suicide attempts, one [of 141 patients] on agomelatine 1mg, three [of 147 patients] on agomelatine 5 mg, one on agomelatine 25 mg, two on paroxetine and none [of 139 patients] on placebo (p. 244).

Suicide and suicide attempts are never mentioned again in the article. Imagine that the data went the other direction – that there were suicide attempts and actual suicides on placebo, but not on medication. In such a case, there would almost certainly be further discussion of how the medication seemed to offer a protective effect against suicide. I give the authors credit for at least presenting the relevant data, but it is quite odd that the data on such a serious matter were simply brushed away.

This reminded me a bit of the Paxil/Seroxat study #329, in which suicide attempts were much more common on drug than placebo, but the study investigators deemed that none of these serious events were related to the medication. Same old story: The drugs don’t cause suicidal ideation and actual suicide – only depression can do that. Does Traci Johnson ring a bell for anyone?

Whitewashing of safety data such as in the case of agomelatine (and here and here) should raise suspicions. More on agomelatine (the "ideal antidepressant?") to come.

Listen to David Healy

David Healy made some insightful comments in the Daily Mail the other day. Everyone should be listening carefully. An excerpt follows, in which all emphasis is added…

Documents prised out of companies by American court cases have become the main way we have of discovering the truth about some of our best-selling drugs.

As well as Prozac, there have been another four or five other drugs exposed in this way.

Two years ago, the painkiller Vioxx was found to double the risk of heart problems; company documents revealed that the drugs sales team were instructed to keep this information from doctors.

Just before Christmas, internal documents suggested attempts were made to play down the serious health risks associated with the top-selling anti-psychotic drug Zyprexa.

Last week similar boxes formed the background to a Panorama programme showing how the company making Seroxat distorted evidence that the drug raised the risk of suicide in children.

The effect of these scandals is to show that something has gone badly wrong with the way our medicines are researched and sold.

--SNIP--

Now company employees analyse the data and medical journalists are hired to write them up for publication. Then Oxbridge and Ivy League professors are paid several thousand pounds to be credited as the authors of these articles.

This is something I've come across personally. Articles have been "ghostwritten" for me by drug companies, and then - when I refused to put my name to them - the same articles have appeared under someone else's name.

I have also seen company memos asking who would be the most "useful" academics to have as the authors of articles already written.

Once published in top medical journals, these confections will deliver more sales than any number of drug representatives, but all too often they are not accurate reports of the trial results.

In other organisations when evidence of disregard for public safety emerges, heads roll. But there have been no resignations following these drug disasters - barely a flicker of embarrassment.

--SNIP--

There's no point appealing to the government drugs watchdog - the MHRA. It is a small outfit entirely funded by the drug industry.

It has never taken any action against the academics who make fraudulent claims in ghostwritten articles, nor doctors working for the companies who repeat such claims, even when they have been shown to be untrue.

So the only other body to turn to is the General Medical Council, whose job it is to investigate the conduct of doctors - but it has shown no inclination to act.

But there is one simple thing we could all do to reclaim the clinical trials. People who participate as guinea pigs should insist the consent form states that the data will be available to all, and without this any drug tester should refuse to sign.

Think Healy has gone mad? Check out some background stories related to his concerns. Try Seroxat/Paxil and the academics who seem to have played the role of company hucksters (here and here). The Zyprexa coverup – too many links to list, but you can start here and here. How about allegedly independent academic physicians making misleadingly positive statements about Seroquel, a drug they “independently” investigated? Ghostwriting? Plenty of evidence available on that – you can start here and here. Cherry picking data to focus on the (minimal) positive results? Try here and here.

Suffice to say that Healy is spot on. When he speaks, I advise paying close attention.

Zyprexa Docs for ALL

Furious Seasons has a link to the Zyprexa docs. He says he has about a third of them posted on his site for anyone to see. Read and enjoy.

Monday, February 05, 2007

Minimal Production

... is what you'll likely be seeing on this site for about a week. The day job calls with extra urgency, so don't expect much. I'll at least try to link to some other interesting happenings in the mental health/pharma blog world.

Friday, February 02, 2007

Then What Happens...

Recently, a reader had an excellent comment to which I responded. The content of these comments seemed like they may be of general interest, so they is reposted below, with very slight trimming of both the reader's comment and my response. All emphases are added in this version...

nab said...

The next logical step from Healy's accurate description:

For all of those patients who have been betrayed - directly or indirectly - or any of us who are on the "outside" should/do not really care whether this was complicity or whether many were (as I think) hoodwinked.

Accountability must be demanded from the entire system (academic - research - clinical): we don't care how you do it, you just need to not have these results. If you are a clinician and you get fooled, then I don't feel you to be gaining personally, but I would like to see the scrutiny that people like you are demanding, or else, how do we know this sort of thing won't keep happening.

That trust is fragile, and that is why (a) I truly appreciate the outrage we can from you - CL Psych and the likes of Healy, Avorn, etc., and (b) am completely frustrated and disturbed by the general lack of such a response from the mainstrean medical community.

For a profession that demands - and is mostly granted - autonomy in its decision-making, I don't really care - to a large extent - how or why bad knowledge was propagated. Obviously those directly responsible should individually be held to account, but at the institutional or professional level, these are examples of a systemic failure.

I feel that many doctors reach Healy's conclusion, shrug their shoulders, and say, "damn, those bastards fooled us, but I didn't do anything personally wrong so whatayagonnado?" Why do we not hear more outrage? Where is the outrage about Vioxx for example?

Regardless, I know Healy means well, but it is quite an indictment of the entire system - not just the pharmaco. or specific academics and clinicians involved. I feel that organized medicine (and doctors generally), love to point the finger at the insurance companies, the pharmaceutical companies, hospitals, anyone besides themselves.

Unfortunately, this causes them to ignore the obvious fact that the practicing doctors on the frontline and the honest and honorable academics researchers have the most power and could be the most effective at remedying these problems. And they ignore this at their own peril because if they don't demand accountability then ultimately soneone has to.

My reply
More scrutiny from practitioners would indeed be a good step. I suspect that a large majority of clinicians have no idea of the degree to which the system has been corrupted.

How can anyone practice Evidence Based Medicine when the Evidence Base is full of half-reported data that is often sold like a used car in such forums as industry-sponsored consensus guidelines, continuing medical education, journal supplements, doctor dinners, and conferences which resemble Disneyland more than a scientific learning environment?

My thoughts: Med schools need to step up their ethics training. Likewise, when the vast majority of of physicians are not trained in research design or statistics during med school, they are not well trained to sniff out the BS in studies.

I believe, perhaps naively, that a class in research/stats and a class that details the numerous examples of what can go wrong when industry and science mix would really awaken med students. That would allow them to have a chance at bucking the system. Reforming the infomercial continuing medical education system would also be a nice touch.

There are surely other ways to go about this, but those are my initial thoughts.
Feel free to add your two cents. Someone has to come up with some answers.